XTL Biopharmaceuticals Ltd Asset Resilience Ratio

Latest as of December 2024: 9.03%

XTL Biopharmaceuticals Ltd asset resilience ratio. XTL Biopharmaceuticals Ltd (H2K2) has an Asset Resilience Ratio of 9.03% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of XTL Biopharmaceuticals Ltd to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€772.00K

≈ $902.55K USD Cash + Short-term Investments

Total Assets

€8.55 Million

≈ $10.00 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of XTL Biopharmaceuticals Ltd (2016–2024)

Asset resilience ratio of XTL Biopharmaceuticals Ltd from 2016 to 2024. This chart shows how XTL Biopharmaceuticals Ltd's Asset Resilience Ratio has changed over time. Read XTL Biopharmaceuticals Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down XTL Biopharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see XTL Biopharmaceuticals Ltd assets under control.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€772.00K	9.03%
Total Liquid Assets	€772.00K	9.03%

Asset Resilience Insights

Limited Liquidity: XTL Biopharmaceuticals Ltd maintains only 9.03% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

XTL Biopharmaceuticals Ltd Industry Peers by Asset Resilience Ratio

Compare XTL Biopharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
CSL Ltd AU:CSL	Biotechnology	0.41%
Genmab A/S CO:GMAB	Biotechnology	23.50%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Xizang Haisco Pharmaceutical Group Co Ltd SHE:002653	Biotechnology	1.69%
Abivax SA American Depositary Shares NASDAQ:ABVX	Biotechnology	4.91%
Bachem Holding AG SW:BANB	Biotechnology	0.00%
Viking Therapeutics Inc NASDAQ:VKTX	Biotechnology	72.03%
SOLENO THERAPEUT. DL-001 F:6XC	Biotechnology	41.74%

XTL Biopharmaceuticals Ltd Asset Resilience Ratio by Year (2016–2024)

XTL Biopharmaceuticals Ltd asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for XTL Biopharmaceuticals Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	9.03%	€772.00K ≈ $902.55K	€8.55 Million ≈ $10.00 Million	-15.91pp
2023-12-31	24.94%	€605.00K ≈ $707.31K	€2.43 Million ≈ $2.84 Million	-13.93pp
2022-12-31	38.87%	€1.63 Million ≈ $1.90 Million	€4.19 Million ≈ $4.89 Million	-8.85pp
2021-12-31	47.72%	€3.16 Million ≈ $3.69 Million	€6.62 Million ≈ $7.74 Million	+10.64pp
2020-12-31	37.08%	€2.41 Million ≈ $2.82 Million	€6.50 Million ≈ $7.60 Million	+5.56pp
2019-12-31	31.52%	€2.27 Million ≈ $2.66 Million	€7.21 Million ≈ $8.43 Million	-25.24pp
2018-12-31	56.76%	€4.87 Million ≈ $5.69 Million	€8.57 Million ≈ $10.03 Million	+14.17pp
2017-12-31	42.59%	€2.81 Million ≈ $3.28 Million	€6.59 Million ≈ $7.70 Million	+28.87pp
2016-12-31	13.72%	€414.00K ≈ $484.01K	€3.02 Million ≈ $3.53 Million	--

pp = percentage points

About XTL Biopharmaceuticals Ltd

F:H2K2 Germany Biotechnology

Market Cap

$6.31 Million

€5.39 Million EUR

Market Cap Rank

#30555 Global

#2666 in Germany

Share Price

€2.28

Change (1 day)

+23.24%

52-Week Range

€0.45 - €2.28

All Time High

€8.26